Hepatitis E Virus Drug Development
AbstractHepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in immunocompromised patients. The current therapy options are limited to the unspecific antivirals Ribavirin (RBV) and pegylated Interferon-α (pegIFN-α). RBV leads to viral clearance in only 80% of patients treated, and is, similar to pegIFN-α, contraindicated in the major risk group of pregnant women, emphasizing the importance of new therapy options. In this review, we focus on the urgent need and current efforts in HEV drug development. We provide an overview of the current status of HEV antiviral research. Furthermore, we discuss strategies for drug development and the limitations of the approaches with respect to HEV. View Full-Text
Share & Cite This Article
Kinast, V.; Burkard, T.L.; Todt, D.; Steinmann, E. Hepatitis E Virus Drug Development. Viruses 2019, 11, 485.
Kinast V, Burkard TL, Todt D, Steinmann E. Hepatitis E Virus Drug Development. Viruses. 2019; 11(6):485.Chicago/Turabian Style
Kinast, Volker; Burkard, Thomas L.; Todt, Daniel; Steinmann, Eike. 2019. "Hepatitis E Virus Drug Development." Viruses 11, no. 6: 485.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.